View Financial HealthXIIlabLtd 배당 및 자사주 매입배당 기준 점검 0/6XIIlabLtd 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-22.2%자사주 매입 수익률총 주주 수익률-22.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩64.6b market cap, or US$43.9m).분석 기사 • Apr 18We Think XIIlabLtd (KOSDAQ:189330) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...공시 • Feb 13XIIlab Co.,Ltd, Annual General Meeting, Mar 30, 2026XIIlab Co.,Ltd, Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 513, yeongdong-daero, gangnam-gu, seoul South Korea분석 기사 • Jan 02Here's Why We're Not At All Concerned With XIIlabLtd's (KOSDAQ:189330) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...New Risk • Aug 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 9.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩48.4b market cap, or US$34.9m).공시 • Aug 16XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 36.772394 billion.XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 36.772394 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,050,068 Price\Range: KRW 5800 Discount Per Security: KRW 104.4 Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,290,000 Price\Range: KRW 5800 Discount Per Security: KRW 104.4 Transaction Features: Rights OfferingNew Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.2b market cap, or US$36.4m).New Risk • May 22New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩40.7b market cap, or US$29.5m).공시 • May 15XIIlab Co.,Ltd has filed a Follow-on Equity Offering in the amount of KRW 17.8647 billion.XIIlab Co.,Ltd has filed a Follow-on Equity Offering in the amount of KRW 17.8647 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,290,000 Price\Range: KRW 5430 Discount Per Security: KRW 97.74 Transaction Features: Rights OfferingReported Earnings • Mar 20Full year 2024 earnings released: ₩851 loss per share (vs ₩1,063 loss in FY 2023)Full year 2024 results: ₩851 loss per share (improved from ₩1,063 loss in FY 2023). Revenue: ₩9.09b (up 148% from FY 2023). Net loss: ₩5.19b (loss narrowed 20% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.공시 • Feb 25XIIlab Co.,Ltd, Annual General Meeting, Mar 26, 2025XIIlab Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 513, yeongdong-daero, gangnam-gu, seoul South Korea분석 기사 • Dec 05We Think XIIlabLtd (KOSDAQ:189330) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Reported Earnings • Aug 17Second quarter 2024 earnings released: ₩307 loss per share (vs ₩268 loss in 2Q 2023)Second quarter 2024 results: ₩307 loss per share (further deteriorated from ₩268 loss in 2Q 2023). Revenue: ₩348.2m (up 3.2% from 2Q 2023). Net loss: ₩1.87b (loss widened 15% from 2Q 2023).분석 기사 • Jul 26Is XIIlabLtd (KOSDAQ:189330) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Reported Earnings • Mar 22Full year 2023 earnings released: ₩1,063 loss per share (vs ₩754 loss in FY 2022)Full year 2023 results: ₩1,063 loss per share (further deteriorated from ₩754 loss in FY 2022). Revenue: ₩3.66b (down 63% from FY 2022). Net loss: ₩6.46b (loss widened 42% from FY 2022).공시 • Mar 20Xiilab Unveils Cutting-Edge AI Technologies At NVIDIA GTCXiilab announced its participation in the global AI conference, NVIDIA GTC, held in San Jose, California, USA, and online from March 18th to 21st, 2024. Xiilab plans to showcase its AI technology at GTC through three main products: AI video analysis service ('VidiGo'), synthetic data generation solution ('X-GEN'), and GPU orchestration solution. The first product, 'VidiGo,' is a cloud-based AI video analysis service that accurately summarizes the core contents of a video without watching it. It can also quickly search for desired video scenes. Users can easily make a database of characters, objects, and dialogues in the video, which significantly improves work efficiency in the media industry. The second product, 'X-GEN,' is a solution for generating synthetic data for AI model training. Especially in areas like disaster response or defense, there is a shortage of data for AI training. X-GEN can provide synthetic data which can replace real data in such rare conditions, even maximizing AI training performance. Xiilab has been applying 'X-GEN' in the digital twin field using the NVIDIA Omniverse. platform, which provides 3D-workflow and simulation capabilities. Since 2023, Xiilab has been successfully leading digital twin construction projects for global companies. Finally, Xiilab will introduce its GPU efficiency enhancement solution 'astrago' at GTC. Equipped with AI training time prediction technology and AI model management capabilities, 'astrago' is designed to optimize GPU utilization. It predicts the usage time of GPUs and combines AI models suitable for specific services, which can maximize GPU efficiency. Users can significantly reduce the costly expenses associated with GPU usage.분석 기사 • Mar 01We're Not Very Worried About XIIlabLtd's (KOSDAQ:189330) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Nov 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2022 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 32% over the past year. Minor Risk Market cap is less than US$100m (₩69.5b market cap, or US$52.7m).New Risk • Jul 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 32% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (₩80.3b market cap, or US$62.8m).Is New 90 Day High Low • Feb 26New 90-day low: ₩36,750The company is down 8.0% from its price of ₩40,000 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 9.0% over the same period.공시 • Feb 25XIIlab Co.,Ltd, Annual General Meeting, Mar 25, 2021XIIlab Co.,Ltd, Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Jan 19New 90-day high: ₩72,000The company is up 125% from its price of ₩32,050 on 21 October 2020. The South Korean market is up 26% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 10.0% over the same period.Is New 90 Day High Low • Dec 22New 90-day high: ₩43,700The company is up 36% from its price of ₩32,200 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 9.0% over the same period.Is New 90 Day High Low • Nov 27New 90-day high: ₩40,000The company is up 56% from its price of ₩25,600 on 28 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 3.0% over the same period.공시 • Jul 17XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 799.94712 million.XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 799.94712 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 50,122 Price\Range: KRW 15960 Transaction Features: Subsequent Direct Listing지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A189330 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A189330 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장XIIlabLtd 배당 수익률 vs 시장A189330의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A189330)n/a시장 하위 25% (KR)1.0%시장 상위 25% (KR)3.7%업계 평균 (Software)1.7%분석가 예측 (A189330) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A189330 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A189330 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A189330 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A189330 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/14 14:45종가2026/05/14 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스XIIlab Co.,Ltd는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jongsun ParkEugene Investment & Securities Co Ltd.
New Risk • Apr 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩64.6b market cap, or US$43.9m).
분석 기사 • Apr 18We Think XIIlabLtd (KOSDAQ:189330) Can Easily Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
공시 • Feb 13XIIlab Co.,Ltd, Annual General Meeting, Mar 30, 2026XIIlab Co.,Ltd, Annual General Meeting, Mar 30, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 513, yeongdong-daero, gangnam-gu, seoul South Korea
분석 기사 • Jan 02Here's Why We're Not At All Concerned With XIIlabLtd's (KOSDAQ:189330) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
New Risk • Aug 30New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 9.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩48.4b market cap, or US$34.9m).
공시 • Aug 16XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 36.772394 billion.XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 36.772394 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,050,068 Price\Range: KRW 5800 Discount Per Security: KRW 104.4 Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,290,000 Price\Range: KRW 5800 Discount Per Security: KRW 104.4 Transaction Features: Rights Offering
New Risk • Jul 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 17% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩49.2b market cap, or US$36.4m).
New Risk • May 22New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 17% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩40.7b market cap, or US$29.5m).
공시 • May 15XIIlab Co.,Ltd has filed a Follow-on Equity Offering in the amount of KRW 17.8647 billion.XIIlab Co.,Ltd has filed a Follow-on Equity Offering in the amount of KRW 17.8647 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,290,000 Price\Range: KRW 5430 Discount Per Security: KRW 97.74 Transaction Features: Rights Offering
Reported Earnings • Mar 20Full year 2024 earnings released: ₩851 loss per share (vs ₩1,063 loss in FY 2023)Full year 2024 results: ₩851 loss per share (improved from ₩1,063 loss in FY 2023). Revenue: ₩9.09b (up 148% from FY 2023). Net loss: ₩5.19b (loss narrowed 20% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings.
공시 • Feb 25XIIlab Co.,Ltd, Annual General Meeting, Mar 26, 2025XIIlab Co.,Ltd, Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 513, yeongdong-daero, gangnam-gu, seoul South Korea
분석 기사 • Dec 05We Think XIIlabLtd (KOSDAQ:189330) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Reported Earnings • Aug 17Second quarter 2024 earnings released: ₩307 loss per share (vs ₩268 loss in 2Q 2023)Second quarter 2024 results: ₩307 loss per share (further deteriorated from ₩268 loss in 2Q 2023). Revenue: ₩348.2m (up 3.2% from 2Q 2023). Net loss: ₩1.87b (loss widened 15% from 2Q 2023).
분석 기사 • Jul 26Is XIIlabLtd (KOSDAQ:189330) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Reported Earnings • Mar 22Full year 2023 earnings released: ₩1,063 loss per share (vs ₩754 loss in FY 2022)Full year 2023 results: ₩1,063 loss per share (further deteriorated from ₩754 loss in FY 2022). Revenue: ₩3.66b (down 63% from FY 2022). Net loss: ₩6.46b (loss widened 42% from FY 2022).
공시 • Mar 20Xiilab Unveils Cutting-Edge AI Technologies At NVIDIA GTCXiilab announced its participation in the global AI conference, NVIDIA GTC, held in San Jose, California, USA, and online from March 18th to 21st, 2024. Xiilab plans to showcase its AI technology at GTC through three main products: AI video analysis service ('VidiGo'), synthetic data generation solution ('X-GEN'), and GPU orchestration solution. The first product, 'VidiGo,' is a cloud-based AI video analysis service that accurately summarizes the core contents of a video without watching it. It can also quickly search for desired video scenes. Users can easily make a database of characters, objects, and dialogues in the video, which significantly improves work efficiency in the media industry. The second product, 'X-GEN,' is a solution for generating synthetic data for AI model training. Especially in areas like disaster response or defense, there is a shortage of data for AI training. X-GEN can provide synthetic data which can replace real data in such rare conditions, even maximizing AI training performance. Xiilab has been applying 'X-GEN' in the digital twin field using the NVIDIA Omniverse. platform, which provides 3D-workflow and simulation capabilities. Since 2023, Xiilab has been successfully leading digital twin construction projects for global companies. Finally, Xiilab will introduce its GPU efficiency enhancement solution 'astrago' at GTC. Equipped with AI training time prediction technology and AI model management capabilities, 'astrago' is designed to optimize GPU utilization. It predicts the usage time of GPUs and combines AI models suitable for specific services, which can maximize GPU efficiency. Users can significantly reduce the costly expenses associated with GPU usage.
분석 기사 • Mar 01We're Not Very Worried About XIIlabLtd's (KOSDAQ:189330) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Nov 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2022 fiscal period end). Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 32% over the past year. Minor Risk Market cap is less than US$100m (₩69.5b market cap, or US$52.7m).
New Risk • Jul 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 32% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (₩80.3b market cap, or US$62.8m).
Is New 90 Day High Low • Feb 26New 90-day low: ₩36,750The company is down 8.0% from its price of ₩40,000 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 9.0% over the same period.
공시 • Feb 25XIIlab Co.,Ltd, Annual General Meeting, Mar 25, 2021XIIlab Co.,Ltd, Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Jan 19New 90-day high: ₩72,000The company is up 125% from its price of ₩32,050 on 21 October 2020. The South Korean market is up 26% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Dec 22New 90-day high: ₩43,700The company is up 36% from its price of ₩32,200 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 9.0% over the same period.
Is New 90 Day High Low • Nov 27New 90-day high: ₩40,000The company is up 56% from its price of ₩25,600 on 28 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 3.0% over the same period.
공시 • Jul 17XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 799.94712 million.XIIlab Co.,Ltd has completed a Follow-on Equity Offering in the amount of KRW 799.94712 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 50,122 Price\Range: KRW 15960 Transaction Features: Subsequent Direct Listing